• Linda Al-Hassany, Peter J Goadsby, DanserA H JanAHJErasmus MC, University Medical Center Rotterdam, Division of Vascular Medicine and Pharmacology, Department of Internal Medicine, Rotterdam, Netherlands., and Antoinette MaassenVanDenBrink.
• Erasmus MC, University Medical Center Rotterdam, Division of Vascular Medicine and Pharmacology, Department of Internal Medicine, Rotterdam, Netherlands.
• Lancet Neurol. 2022 Mar 1; 21 (3): 284-294.

AbstractMigraine is the second most disabling disorder across all age groups worldwide. Since 2018, two classes of drugs that inhibit the actions of calcitonin gene-related peptide (CGRP), which is implicated in migraine pathophysiology, have become available: gepants (CGRP receptor antagonists) and monoclonal antibodies directed against CGRP or its receptor. Despite phase 3 clinical trials and some real world evidence, knowledge of the pharmacology and related clinical effects of these drugs is low, and trial data are not necessarily generalisable to all populations. Additionally, several pharmacodynamic processes affected by both gepants and monoclonal antibodies to CGRP and its receptor are not fully understood. Sex, body-mass index, age, ethnic background, and other characteristics, which are subject to considerable variation, might affect the pharmacokinetics of these therapies, especially gepants. If studies confirm this possibility, these characteristics could assist clinicians in choosing the optimal treatment for patients with migraine. The choice between a gepant or monoclonal antibody should be made carefully, taking into consideration a patient's comorbidities and preferences. As more becomes known about CGRP-targeted therapies, management based on the characteristics of patients could have a more prominent role in the treatment of migraine.Copyright © 2022 Elsevier Ltd. All rights reserved.

20 keywords...

hide…